MED13-KCNJ2 Fusion FISH Probe
The MED13-KCNJ2 Fusion FISH Probe is used to confirm a fusion of the MED13 and KCNJ2 genes. The fusion of the MED13 and KCNJ2 genes has been associated with Breast Invasive Carcinoma. These probes are FISH confirmed on normal peripheral blood in both interphase nuclei and metaphase spreads before shipment. Typical turnaround time for this product is 7-14 days after purchase.
** This product is for in vitro and research use only. This product is not intended for diagnostic use. Please note that both genes fall on the same chromosome and inter-chromosomal detection may be difficult to detect depending on the genes proximity to one another. Please consult our support staff before ordering this product to ensure that the probe can be designed to meet your specific needs.
| SKU | Test Kits | Buffer | Dye Color | Order Now |
|---|---|---|---|---|
| MED13-KCNJ2-20-ORGR (Standard Design) | 20 (40 μL) | 200 μL |
|
|
| MED13-KCNJ2-20-RERE | 20 (40 μL) | 200 μL |
|
|
| MED13-KCNJ2-20-REOR | 20 (40 μL) | 200 μL |
|
|
| MED13-KCNJ2-20-REGO | 20 (40 μL) | 200 μL |
|
|
| MED13-KCNJ2-20-REGR | 20 (40 μL) | 200 μL |
|
|
| MED13-KCNJ2-20-REAQ | 20 (40 μL) | 200 μL |
|
|
| MED13-KCNJ2-20-ORRE | 20 (40 μL) | 200 μL |
|
|
| MED13-KCNJ2-20-OROR | 20 (40 μL) | 200 μL |
|
|
| MED13-KCNJ2-20-ORGO | 20 (40 μL) | 200 μL |
|
|
| MED13-KCNJ2-20-ORAQ | 20 (40 μL) | 200 μL |
|
|
| MED13-KCNJ2-20-GORE | 20 (40 μL) | 200 μL |
|
|
| MED13-KCNJ2-20-GOOR | 20 (40 μL) | 200 μL |
|
|
| MED13-KCNJ2-20-GOGO | 20 (40 μL) | 200 μL |
|
|
| MED13-KCNJ2-20-GOGR | 20 (40 μL) | 200 μL |
|
|
| MED13-KCNJ2-20-GOAQ | 20 (40 μL) | 200 μL |
|
|
| MED13-KCNJ2-20-GRRE | 20 (40 μL) | 200 μL |
|
|
| MED13-KCNJ2-20-GROR | 20 (40 μL) | 200 μL |
|
|
| MED13-KCNJ2-20-GRGO | 20 (40 μL) | 200 μL |
|
|
| MED13-KCNJ2-20-GRGR | 20 (40 μL) | 200 μL |
|
|
| MED13-KCNJ2-20-GRAQ | 20 (40 μL) | 200 μL |
|
|
| MED13-KCNJ2-20-AQRE | 20 (40 μL) | 200 μL |
|
|
| MED13-KCNJ2-20-AQOR | 20 (40 μL) | 200 μL |
|
|
| MED13-KCNJ2-20-AQGO | 20 (40 μL) | 200 μL |
|
|
| MED13-KCNJ2-20-AQGR | 20 (40 μL) | 200 μL |
|
|
| MED13-KCNJ2-20-AQAQ | 20 (40 μL) | 200 μL |
|
KCNJ2 Gene Summary
Potassium channels are present in most mammalian cells, where they participate in a wide range of physiologic responses. The protein encoded by this gene is an integral membrane protein and inward-rectifier type potassium channel. The encoded protein, which has a greater tendency to allow potassium to flow into a cell rather than out of a cell, probably participates in establishing action potential waveform and excitability of neuronal and muscle tissues. Mutations in this gene have been associated with Andersen syndrome, which is characterized by periodic paralysis, cardiac arrhythmias, and dysmorphic features. [provided by RefSeq, Jul 2008]
Gene Name: Potassium Voltage-gated Channel Subfamily J Member 2
Chromosome: CHR17: 68165675 -68176183
Locus: 17q24.3
MED13 Gene Summary
This gene encodes a component of the mediator complex (also known as TRAP, SMCC, DRIP, or ARC), a transcriptional coactivator complex thought to be required for the expression of almost all genes. The mediator complex is recruited by transcriptional activators or nuclear receptors to induce gene expression, possibly by interacting with RNA polymerase II and promoting the formation of a transcriptional pre-initiation complex. The product of this gene is proposed to form a sub-complex with MED12, cyclin C, and CDK8 that can negatively regulate transactivation by mediator. [provided by RefSeq, Jul 2008]
Gene Name: Mediator Complex Subunit 13
Chromosome: CHR17: 60019965 -60142643
Locus: 17q23.2
Gene Diseases
The MED13 KCNJ2 Fusion has been associated with the following diseases:
| Disease Name |
|---|
| Breast Invasive Carcinoma |
FISH Probe Protocols
| Protocol, Procedure, or Form Name | Last Modified | Download |
|---|